Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases
Source abstract
Abstract
Brain diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), brain tumors, and stroke, remain difficult to treat due to the restrictive nature of the blood-brain barrier (BBB). Traditional Chinese medicine (TCM) bioactive compounds offer multitarget therapeutic potential, but their clinical translation is limited by poor solubility, instability, rapid clearance, and insufficient brain exposure. Nanodelivery systems can enhance pharmacokinetics and enable brain-targeted delivery via engineered nanocarriers that exploit multiple BBB-crossing routes. This review summarizes nanotechnology-based strategies that facilitate efficient BBB transport, targeted brain accumulation, and microenvironment-responsive release of TCM-derived bioactives. Emphasis is placed on rational nanocarrier design, including biomimetic surface modification, physicochemical optimization, multicomponent integration, and stimulus-responsive systems that improve spatiotemporal control and therapeutic precision. Collectively, these strategy-oriented principles provide a translational framework for advancing nano-enabled TCM therapeutics in complex brain disorders.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and alzheimer's disease10.1038/jcbfm.2015.76 ↗
2. Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders10.1016/j.progpolymsci.2014.12.002 ↗
3. Classical active ingredients and extracts of Chinese herbal medicines: Pharmacokinetics, pharmacodynamics, and molecular mechanisms for ischemic stroke10.1155/2021/8868941 ↗
4. Multi-target strategy and experimental studies of traditional Chinese medicine for Alzheimer's disease therapy10.2174/1568026615666150813144003 ↗
5. Corrigendum to "Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: a mechanism review" [ Biomed. Pharamacother. 133, (2021) 110968]10.1016/j.biopha.2023.114979 ↗
6. The pathogenesis and treatment mechanism of Parkinson's disease from the perspective of traditional Chinese medicine10.1016/j.phymed.2022.154044 ↗
7. Ameliorating effects of traditional Chinese medicine preparation, Chinese materia medica and active compounds on ischemia/reperfusion-induced cerebral microcirculatory disturbances and neuron damage10.1016/j.apsb.2014.11.002 ↗
8. Targeted delivery of nano-therapeutics for major disorders of the central nervous system10.1007/s11095-013-1122-4 ↗
9. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings10.1111/j.1476-5381.2011.01557.x ↗
10. Current advances in delivery of biotherapeutics across the blood-brain barrier10.2174/157016311795563866 ↗
11. Lipid nanoparticles and active natural compounds: a perfect combination for pharmaceutical applications10.2174/0929867326666190614123835 ↗
12. Bioavailability enhancers of herbal origin: an overview10.1016/S2221-1691(13)60060-X ↗
13. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the global burden of disease study 202110.1016/S1474-4422(24)00038-3 ↗
14. Disease · Lancet · 2025 · 406 · 187310.1016/S0140-6736(25)01637-X ↗
15. Progress in the treatment of central nervous system diseases based on nanosized traditional Chinese medicine
16. Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies10.1016/j.mattod.2020.02.001 ↗
17. Blood-brain barrier-penetrating siRNA nanomedicine for Alzheimer's disease therapy10.1126/sciadv.abc7031 ↗
18. The combination of nanotechnology and traditional Chinese medicine (TCM) inspires the modernization of TCM: review on nanotechnology in TCM-based drug delivery systems10.1007/s13346-021-01029-x ↗
19. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases10.1002/adma.201801362 ↗
20. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases10.1016/j.jconrel.2016.05.044 ↗
21. Anti-Parkinsonian therapy: strategies for crossing the blood-brain barrier and nano-biological effects of nanomaterials10.1007/s40820-022-00847-z ↗
22. Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders10.3389/fphys.2020.00914 ↗
23. Activation of NMDA receptors in brain endothelial cells increases transcellular permeability10.1186/s12987-022-00364-6 ↗
24. Functional morphology of the blood-brain barrier in health and disease10.1007/s00401-018-1815-1 ↗
25. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases10.1038/s41568-019-0205-x ↗
26. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis10.2217/nnm.16.15 ↗
27. Blood brain barrier: a challenge for effectual therapy of brain tumors10.1155/2015/320941 ↗
28. Agile delivery of protein therapeutics to CNS10.1016/j.jconrel.2014.06.017 ↗
29. Establishment and dysfunction of the blood-brain barrier10.1016/j.cell.2015.10.067 ↗
30. Engaging neuroscience to advance translational research in brain barrier biology10.1038/nrn2995 ↗
31. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery10.1038/nrd.2015.21 ↗
32. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders10.1038/nrn3114 ↗
33. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity10.1186/s12987-020-00230-3 ↗
34. Extracellular vesicles as a potential therapy for stroke
35. In vitro models of the blood-brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use10.1177/0271678X16630991 ↗
36. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies10.1016/j.biomaterials.2019.119491 ↗
37. Crossing the blood-brain barrier: recent advances in drug delivery to the brain10.1007/s40263-016-0405-9 ↗
38. Nanomaterials for drug delivery to the central nervous system10.3390/nano9030371 ↗
39. Abdominal functional electrical stimulation to improve respiratory function after spinal cord injury: a systematic review and meta-analysis10.1038/sc.2016.31 ↗
40. Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme
41. Transcytosis to cross the blood brain barrier, new advancements and challenges10.3389/fnins.2018.01019 ↗
42. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders10.1016/j.progpolymsci.2007.05.014 ↗
43. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases10.1016/j.jconrel.2017.08.033 ↗
44. Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems10.1016/j.addr.2019.06.008 ↗
45. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery10.1080/21691401.2018.1561457 ↗
46. Neuroprotective effect of biosynthesised gold nanoparticles synthesised from root extract of Paeonia moutan against Parkinson disease - in vitro &in vivo model10.1016/j.jphotobiol.2019.111635 ↗
47. Piperine-coated gold nanoparticles alleviate Paraquat-Induced neurotoxicity in Drosophila melanogaster10.1021/acschemneuro.0c00366 ↗
48. Quercetin carbon quantum dots: dual-target therapy for intracerebral hemorrhage in mice10.1186/s13041-024-01159-6 ↗
49. Correction: carbon quantum dots of ginsenoside Rb1 for application in a mouse model of intracerebral hemorrhage10.1186/s12951-024-02497-2 ↗
50. Green functional carbon dots derived from herbal medicine ameliorate blood-brain barrier permeability following traumatic brain injury10.1007/s12274-022-4616-8 ↗
51. Correction to "Lipid-Coated MCM-41 Mesoporous Silica Nanoparticles Loaded with Berberine Improved Inhibition of Acetylcholine Esterase and Amyloid Formation"10.1021/acsbiomaterials.3c00989 ↗
52. Quercetin encapsulation in modified silica nanoparticles: potential use against Cu(II)-induced oxidative stress in neurodegeneration10.1016/j.jinorgbio.2015.01.001 ↗
53. Key Lipoprotein receptor targeted echinacoside-liposomes effective against Parkinson's Disease in mice model10.2147/IJN.S468942 ↗
54. Quercetin-loaded nanoliposomes as a novel neuroprotective strategy for alzheimer's Disease
55. Enhanced cognitive function in mice through intranasal delivery of sinapic acid via chitosan-coated solid lipid nanoparticles10.1016/j.ijpharm.2025.125565 ↗
56. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery10.1111/j.2042-7158.2010.01225.x ↗
57. Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease10.1007/s12017-013-8261-y ↗
58. Sialic acid-based glycoconjugation on Myricetin-encapsulated cationic nanocarriers for the treatment of alzheimer's10.1007/s11095-025-03877-5 ↗
59. Intra-nasal delivery of quercetin-loaded nanostructured lipid carriers (NLCs) in the management of Alzheimer's disease: formulation, in vitro and in vivo assessment10.1007/s12035-025-05137-4 ↗
60. Food-grade Quercetin-loaded nanoemulsion ameliorates effects associated with Parkinson's Disease and cancer: studies employing a transgenic C. elegans model and human cancer cell lines10.3390/antiox11071378 ↗
61. Honokiol-loaded nanoemulsion for glioblastoma treatment: statistical optimization, physicochemical characterization, and an in vitro toxicity assay10.3390/pharmaceutics15020448 ↗
62. Pterostilbene nanoemulsion promotes Nrf2 signaling pathway to downregulate oxidative stress for treating Alzheimer's disease10.1016/j.ijpharm.2024.124002 ↗
63. Antitumor efficacy of a novel CLA-PTX microemulsion against brain tumors: in vitro and in vivo findings
64. Brain targeted curcumin loaded turmeric oil microemulsion protects against trimethyltin induced neurodegeneration in adult zebrafish: a pharmacokinetic and Pharmacodynamic insight10.1007/s11095-022-03467-9 ↗
65. Traditional Chinese medicine borneol-based polymeric micelles intracerebral drug delivery system for precisely pathogenesis-adaptive treatment of ischemic stroke
66. A triple-targeted rutin-based self-assembled delivery vector for treating ischemic stroke by vascular normalization and anti-inflammation via ACE2/Ang1-7 signaling10.1021/acscentsci.3c00377 ↗
67. Intranasal pterostilbene nanoparticles delivery alleviates neuroinflammation and brain injury after intracerebral hemorrhage
68. A novel brain-targeting nanoparticle loaded with biatractylolide and its protective effect on Alzheimer's disease10.3390/ph18060809 ↗
69. Hybrid exosome-liposome nanoparticles for dual modulation of neuroinflammation and lipid metabolism in ischemic stroke10.1021/acsnano.5c11417 ↗
70. Chitosan-Ellagic acid nanohybrid for mitigating rotenone-induced oxidative stress10.1021/acsami.9b21215 ↗
71. Intranasal resveratrol delivery to the brain with chitosan-decorated bovine serum albumin nanoparticles: advancing Alzheimer's management in old female rats through QbD-based optimization, in vitro evaluation, and in vivo exploration10.1016/j.ijbiomac.2025.143300 ↗
72. Glucose-modified BSA/procyanidin C1 NPs penetrate the blood-brain barrier and alleviate neuroinflammation in Alzheimer's disease models10.1016/j.ijbiomac.2024.131739 ↗
73. Plant-derived exosomes as cell homogeneous nanoplatforms for brain biomacromolecules delivery ameliorate mitochondrial dysfunction against Parkinson's disease10.1016/j.nantod.2024.102438 ↗
74. Panax notoginseng: derived exosome-like nanoparticles attenuate ischemia reperfusion injury via altering microglia polarization10.1186/s12951-023-02161-1 ↗
75. Nanostructured lipid carriers as a drug delivery system: a comprehensive review with therapeutic applications10.1016/j.ipha.2024.09.005 ↗
76. Inorganic nanomaterials as carriers for drug delivery10.1166/jbn.2016.2122 ↗
77. Advanced application of nanotechnology in active constituents of traditional Chinese Medicines10.1186/s12951-023-02165-x ↗
78. Application of green gold nanoparticles in cancer therapy and diagnosis10.3390/nano12071102 ↗
79. Recent advances in functional carbon quantum dots for antitumour10.2147/IJN.S334012 ↗
80. A new strategy for intracellular delivery of enzyme using mesoporous silica nanoparticles: superoxide dismutase10.1021/ja3105208 ↗
81. Synthesis of mesoporous silica nanoparticles10.1039/c3cs35405a ↗
82. Approach to deliver two antioxidant enzymes with mesoporous Silica nanoparticles into cells10.1021/acsami.6b05834 ↗
83. Bridging size and charge effects of mesoporous silica nanoparticles for crossing the blood-brain barrier
84. Nano-based drug delivery systems for active ingredients from traditional Chinese medicine: harnessing the power of nanotechnology
85. Optimization of Gefitinib-Loaded nanostructured lipid carrier as a biomedical tool in the treatment of metastatic lung cancer10.3390/molecules28010448 ↗
86. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches
87. Development of Salvianolic acid B-Tanshinone II A-Glycyrrhetinic acid compound liposomes: formulation optimization and its effects on proliferation of hepatic stellate cells10.1016/j.ijpharm.2013.12.040 ↗
88. In vitro Co-Delivery evaluation of novel pegylated nano-liposomal herbal drugs of silibinin and glycyrrhizic acid (Nano-Phytosome) to hepatocellular carcinoma cells
89. Solid lipid nanoparticles: a review on recent perspectives and patents10.1080/13543776.2020.1720649 ↗
90. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art10.1016/S0939-6411(00)00087-4 ↗
91. Solid lipid nanoparticles: production, characterization and applications10.1016/S0169-409X(01)00105-3 ↗
92. Nanostructured lipid matrices for improved microencapsulation of drugs10.1016/S0378-5173(02)00180-1 ↗
93. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery10.1208/s12249-010-9563-0 ↗
94. Microemulsions: a potential delivery system for bioactives in food10.1080/10408690590956710 ↗
95. Nano-emulsions and micro-emulsions: clarifications of the critical differences10.1007/s11095-010-0309-1 ↗
96. Nanotargeted agents: an emerging therapeutic strategy for breast cancer10.2217/nnm-2018-0481 ↗
97. Ferrimagnetic mPEG-b-PHEP copolymer micelles loaded with iron oxide nanocubes and emodin for enhanced magnetic hyperthermia-chemotherapy10.1093/nsr/nwz201 ↗
98. Progress of drug-loaded polymeric micelles into clinical studies10.1016/j.jconrel.2014.06.042 ↗
99. Codelivery of curcumin and doxorubicin by MPEG-PCL results in improved efficacy of systemically administered chemotherapy in mice with lung cancer
100. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier10.3390/polym3031377 ↗